Posts

Madrigal’s resmetirom could have higher price defence i...

The revised report reveals the fair pricing benchmarks for two NASH treatments, ...

Ghana becomes first country to approve Oxford’s malaria...

The West African country has approved the vaccine for use in children ages betwe...

STAT+: ‘Style over substance?’ Express Scripts launches...

Amid increasing scrutiny of pharmacy benefit managers, Express Scripts is launch...

STAT+: Congress is launching a tobacco harm reduction c...

Congress is launching a tobacco harm reduction caucus. Its biggest supporter so ...

STAT+: Medicare advisers endorse reforms to lower drug ...

MedPAC wants Medicare to cap payments for drugs that the FDA greenlit via its ac...

Listen: How the legal battle over abortion could thwart...

Is pharma facing an existential threat? How do you get CEOs to speak out? And wh...

STAT+: Flawed AI algorithms can cause harm in medicine....

There are a lot of ways that AI can go awry in health and medicine. A team of re...

Scientists, going on a bear hunt, find a potential way ...

Manuela Thienel and her 38 collaborators — it takes a village to study a bear — ...

Promising new malaria vaccine for kids approved in Ghana

Ghana on Thursday became the first country to approve a new malaria vaccine for ...

STAT+: Federal group studying surprise ambulance bills ...

The federal committee in charge of finding ways to stop surprise billing from gr...

STAT+: Google will let health care customers test its g...

Google will let health care customers test its generative AI model, ramping up t...

Abortion drug battle will head to Supreme Court after a...

A federal appeals court is allowing continued access to a common abortion medica...

STAT+: Pear Therapeutics dreamt of huge revenues and ‘c...

Pear Therapeutics said it would grow from $4 million in 2021 to a whopping $125 ...

Opinion: ‘Internist’ is a confusing, outdated term. It’...

"Internist" is a confusing, outdated term. It's time to embrace "internal medici...

STAT+: FDA staff leaned toward rejecting Sarepta gene t...

Reviewers at the FDA were leaning toward rejecting a closely watched gene therap...

STAT+: Sickle cell gene therapies could be cost-effecti...

The pending arrival of the treatments is causing a degree of trepidation, becaus...